DR JOHN STONE gives Overview Of #IgG4 New non B cell depleter #obexelimab N=194 in RCT To add to B cell depletion w #Inebilizumab Off label but used also #Rituximab #steroids #Immunesuppressives Other investigational drugs Ex #JAKi #EULAR2026 @RheumNow #OP018 #RULARbest https://t.co/Y4saGYcdww

• https://x.com/Janetbirdope/status/2062551135592804656/photo/1
• https://x.com/Janetbirdope/status/2062551135592804656/photo/1
• https://x.com/Janetbirdope/status/2062551135592804656/photo/1

💉 Does ivarmacitinib (selective #JAK1i work in nr-axSpA? Phase 3 RCT (n=304): ASAS40 39.7% vs 24.8% placebo at week 12 with sustained benefit at week 24 #OP0237 #EULAR2026 @RheumNow https://t.co/kofXnPp6qQ

• https://x.com/Nellziade/status/2062545287885787380/photo/1

🔬 Can filgotinib improve axSpA? OLINGUITO (Phase 3 RCT, n=495): YES! ASAS40 39.5% vs 21% (r-axSpA) at week 16 #OP0234 #EULAR2026 @RheumNow https://t.co/0vj2KqSS1b

• https://x.com/Nellziade/status/2062544406004060651/photo/1

🧬 Do biomarkers predict #zasocitinib response in PsA? YES: TYK2/IL-17 pathway markers predict ACR20 in 290pts Phase 2b RCT #OP0184 #EULAR2026 @RheumNow https://t.co/AVlyrauI5q

• https://x.com/Nellziade/status/2062542434538602642/photo/1

❤️ Do biologics differ in MACE risk in PsA? YES - JAKi highest risk after 2.5yrs vs TNFi/IL-17i/IL-23i in a retrospective cohort of 22,246pts. OP0181 #EULAR2026 @RheumNow https://t.co/eQdBtMfRAY

• https://x.com/Nellziade/status/2062541174926172225/photo/1

DESIR Cohort 10-year data (OP0102): SIJ structural lesions in #axSpA progress slowly, but prior MRI bone marrow oedema predicts later structural damage. bDMARD exposure was associated with less erosion progression supporting early biologic treatment Abstr OP0102 @RheumNow

JAKi vs ABA in RA-ILD: emulated target trial (n=1,162), JAKi with worse composite respiratory outcomes (HR 1.57) and all-cause mortality (HR 1.59) vs ABA over 5 yrs. JAKi with ↑ pneumonia risk. In RA-ILD, ABA may be the preferred choice? @RheumNow #EULAR2026 POS0813 #EULARBEST

#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh

• https://x.com/DrMiniDey/status/2062485261921964380/photo/1

#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0

• https://x.com/DrMiniDey/status/2062483752043872563/photo/1

#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio

• https://x.com/DrMiniDey/status/2062479473879261672/photo/1

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

• https://x.com/DrMiniDey/status/2062474451246318046/photo/1

FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h

• https://x.com/RHEUMarampa/status/2062458264655134775/photo/1

TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205